top of page


FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold
The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold.

nuaxia
Oct 232 min read


Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

nuaxia
Oct 232 min read


Gilead signs Vir Biotechnology oncology collaboration worth up to $1.9 billion for masked T-cell engagers
Gilead has entered a global oncology collaboration with Vir Biotechnology worth potentially $1.9 billion to develop masked T-cell engagers for solid tumours.

nuaxia
Oct 152 min read


Escugen and Sovran expand collaboration to co-develop pan-tumour bispecific ADC
Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.

nuaxia
Sep 172 min read


TScan Therapeutics cuts workforce by 75% and pauses Phase 3 programme in strategic pivot
TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours.

nuaxia
Sep 32 min read
bottom of page